Treatment for Antisocial Personality Disorder: Approaches and Evidence
Author: Ukrainian Psychological Hub · Published: October 13, 2026 · Editorial Policy
Treatment for antisocial personality disorder (ASPD) centers on reducing harmful and impulsive behavior, improving emotional and interpersonal regulation, addressing co-occurring conditions, and building reliable participation in everyday life. Structured psychological interventions are the main focus of treatment planning, but evidence varies considerably by approach and population. The most important newer finding is a 2025 randomized trial in which antisocial personality disorder–adapted mentalization-based treatment reduced measured aggression among men under community probation supervision. This is encouraging disorder-specific evidence, although it does not establish a universally effective treatment or a cure. Fonagy and colleagues, 2025.
The practical treatment question is therefore more precise than “Can ASPD be cured?” It asks which difficulties can change, which interventions have actually been tested in people with ASPD, which outcomes a study measured, and what a clinician should do when evidence remains uncertain. The NICE clinical guideline on ASPD recommends active engagement, appropriately adapted cognitive and behavioral interventions, treatment of co-occurring mental disorders, and careful attention to safety. This article examines each approach and its supporting evidence. For the diagnostic criteria and evaluation of ASPD, see Antisocial Personality Disorder: Diagnosis and Treatment.
What Does Successful Treatment for ASPD Mean?
Antisocial personality disorder is a clinical diagnosis involving persistent patterns of disregarding other people's rights and difficulties involving behavior, responsibility, interpersonal relationships, and regulation of impulses. In the DSM-5-TR categorical system, diagnosis in adults requires a longitudinal developmental assessment, including evidence of conduct-disorder symptoms before age 15. The World Health Organization's ICD-11 instead classifies personality disorder primarily by severity and optionally describes maladaptive traits, including dissociality and disinhibition. These different diagnostic frameworks matter because treatment studies often recruit participants using older categorical criteria, while contemporary clinicians may formulate needs dimensionally. WHO ICD-11 Clinical Descriptions and Diagnostic Requirements, 2024.
A treatment outcome may be a reduction in physical aggression, threats, repeated rule violations, impulsive decisions, substance-related harm, or unstable social and occupational functioning. Other meaningful goals include greater awareness of one's reactions, more consistent attendance at appointments, reduced exposure of family members to harm, safer conflict management, sustained housing or employment, and improved relationships. These measures have different significance. Fewer aggressive incidents are important even when other personality-related traits remain present; decreased reconviction cannot automatically demonstrate improved empathy or well-being.
Treatment is best understood as an individualized plan involving a person's specific impairments and risks. A person may have ASPD without a recent criminal conviction. Conversely, a history of arrest or an aggressive act does not establish ASPD. Neither a self-report screening score nor a family member's description can substitute for professional assessment. The English Hub's clinical personality-disorder assessment guide explains why structured history-taking, differential diagnosis, and clinical judgment are necessary.
What Does the Overall Research Say?
The most widely cited systematic synthesis of ASPD-specific psychotherapy trials is the 2020 Cochrane review by Gibbon and colleagues. It included 19 studies of psychological interventions, but only 10 studies with 605 participants contributed usable data to the review's assessed outcomes. Four studies focused exclusively on people with ASPD; many others examined ASPD subgroups recruited for substance-use or forensic treatment. Participants were predominantly men. Differences between interventions, comparison conditions, settings, outcomes, and methodological quality prevented confident identification of one established treatment. The certainty of important findings was generally low or very low. Gibbon et al., Cochrane, 2020.
This conclusion applies to the research available when that review was conducted. It should be interpreted alongside newer trials rather than treated as a permanent verdict about treatability. A treatment can reasonably be offered under clinical guidance when the expected benefits, risks, alternatives, and evidence limitations are explained. A promising individual trial can strengthen confidence in a particular method and outcome while leaving questions about replication, population differences, long-term effects, and cost unanswered.
A key distinction is between a clinical guideline recommendation and high-certainty evidence of disorder-specific effectiveness. Guidelines can recommend an intervention on the basis of imperfect direct trials, evidence from related behavioral problems, clinical experience, feasibility, and potential safety benefits. NICE CG77, first issued in 2009 and reviewed in 2024, explicitly acknowledges the limited ASPD treatment evidence and draws upon research concerning aggression, substance-use treatment, antisocial behavior, and offending. Its recommendations must be read with that evidentiary background in mind. NICE CG77.
Mentalization-Based Treatment for ASPD: The Important 2025 Trial
Mentalization is the capacity to think about one's own and other people's feelings, beliefs, intentions, and reactions. Under anger, perceived threat, humiliation, or conflict, mentalizing can become less flexible; a person may assume hostile intent or act on an immediate interpretation. Mentalization-based treatment adapted for ASPD (MBT-ASPD) aims to help participants notice these processes, regulate the escalation of anger, question automatic assumptions, and respond with greater deliberation.
What the MOAM randomized trial tested
The Mentalization for Offending Adult Males (MOAM) study was a multicenter, assessor-masked randomized controlled trial in England and Wales. Researchers enrolled 313 men aged 21 or older who met DSM-5 ASPD criteria, had been convicted of an offense, were supervised in community probation services, and had a specified level of measured aggression at enrollment. Participants were assigned to probation as usual or probation plus an ASPD-adapted mentalization program. The program offered 12 months of weekly 75-minute group therapy and monthly 50-minute individual sessions, with follow-up assessment over 24 months. Fonagy et al., 2025.
At the primary 12-month endpoint, mean aggression scores on the Overt Aggression Scale–Modified were 90 in the MBT-ASPD group and 186 in the probation-as-usual group. The adjusted mean between-group difference was −73.5 points (95% confidence interval −113.7 to −33.2), favoring MBT-ASPD. The reported standardized effect was 0.74. These are outcomes on a study-specific measure, rather than a 74% reduction in violence or an estimate of effectiveness for all adults diagnosed with ASPD. Primary trial report.
The trial is important because it directly studied a defined ASPD population, used random allocation, assessed aggression as a prespecified primary outcome, and compared the adapted treatment with a realistic service condition. It also involved trained clinicians and an organized probation pathway. Clinicians and readers should understand that this tested a structured, ASPD-specific program; a generic group discussion or unsupervised online mentalization exercise is not equivalent to the intervention evaluated.
What the findings establish—and what remains open
The findings support MBT-ASPD as a promising option for reducing aggression in adult men with ASPD under probation supervision. They do not yet prove the same magnitude of benefit for women, people without criminal-justice involvement, adolescents, individuals with markedly different treatment access, or patients whose primary difficulty is unrelated to aggression. The comparison was probation services as usual, rather than another equally intensive specialist psychotherapy, so relative superiority to other psychotherapies is unresolved.
The reported trial involved a population at substantial clinical and social risk. Eight participants died or were presumed deceased during follow-up, all in the probation-as-usual arm; the investigators did not attribute these deaths to trial procedures. This observation requires careful interpretation and cannot be treated as evidence that MBT prevents death, because mortality was not the study's main treatment endpoint. Longer-term durability of change, differential benefit across profiles, replication outside forensic pathways, and broad implementation remain open research questions. Fonagy et al., trial findings and safety report.
Cognitive-Behavioral and Structured Behavioral Approaches
Cognitive-behavioral interventions aim to change relationships among situations, interpretations, impulses, decisions, and consequences. In ASPD treatment they can target anger escalation, hostile interpretations, immediate reward seeking, poor problem-solving, disregard of future consequences, and interpersonal conflict. A structured program might practice recognizing triggers, pausing before action, identifying alternatives, rehearsing responses, evaluating consequences, and applying skills in real situations.
NICE CG77 recommends considering group-based cognitive and behavioral interventions in community or mental health settings, including for people with substance-use problems, when targeting impulsivity, interpersonal difficulties, and antisocial behavior. For people with a history of offending, the guideline also recommends considering relevant cognitive and behavioral programs aimed at reducing reoffending and harmful behavior, with duration and intensity adapted to assessed risk and with active support for attendance.
Why a clinical recommendation does not equal a proven universal response
The 2020 Cochrane psychological-treatment review found that outcomes and study designs were too heterogeneous to show consistent benefits of cognitive-behavioral therapy (CBT) for ASPD itself. In one trial involving 52 participants, CBT plus treatment as usual was not convincingly better than treatment as usual on the reported physical-aggression outcome; the confidence interval remained wide. This is a limitation of the trial evidence, not evidence that every CBT-informed strategy is futile. Gibbon et al., 2020.
Programs developed to reduce criminal recidivism present an additional interpretation problem. A program may improve behavior within probation or institutional systems, but not demonstrate lasting changes in personality functioning. Studies may count convictions or official incidents without comprehensively assessing everyday relationships, employment, personal goals, or the experiences of people affected by harm. Good ASPD care therefore establishes what an intervention targets and separately measures those targets.
Group therapy, individual therapy, and service setting
Group treatment can provide repeated opportunities to practice communication, manage disagreement, and apply skills under supervision. Individual sessions may be especially useful for assessing risk, building motivation, discussing sensitive events, and connecting general techniques with the person's actual triggers. Which format is appropriate depends on clinical assessment, available staff, group safety, participant readiness, accessibility, and co-occurring conditions. There is no reliable basis for promising that either individual or group psychotherapy is categorically superior for everyone with ASPD.
NICE emphasizes continuity between settings, adaptation where literacy or cognitive difficulties make standard materials less accessible, and regular individual contact even when treatment is mainly group-based. Criminal-justice supervision, when present, has distinct functions from clinical care; clear explanation of information sharing, confidentiality, and legal obligations can support informed participation. NICE recommendations on access and intervention delivery.
Schema Therapy: Encouraging Results and Important Limits
Schema therapy attempts to address persistent emotional, interpersonal, and behavioral patterns using a structured integration of cognitive, behavioral, experiential, and relationship-focused techniques. Its conceptual framework can be clinically relevant to difficulties involving mistrust, entitlement, anger, shame, emotional detachment, and the ways a person responds to perceived vulnerability. These are treatment formulations, not alternative criteria for diagnosing ASPD.
A randomized clinical trial reported by Bernstein and colleagues compared three years of schema therapy with treatment as usual among 103 men in eight high-security forensic hospitals in the Netherlands. The sample included several personality-disorder diagnoses, including antisocial, narcissistic, borderline, and paranoid personality disorders. The investigators reported an advantage for schema therapy on measures of rehabilitation and personality-disorder symptoms, with participants in both arms showing improvement. Bernstein et al., 2023.
The design supports investigation of schema therapy within specialist forensic personality-disorder treatment. Because participants had mixed diagnoses and received multiple other treatment components in a highly specialized setting, the results should not be presented as proof of a specific benefit for every community-dwelling person with ASPD. The treatment lasted three years and required substantial institutional resources. Any general clinical application must account for the diagnosis mix, setting, availability of trained therapists, risk profile, and actual outcomes measured.
Dialectical Behavior Therapy, Problem-Solving, and Other Approaches
Dialectical behavior therapy (DBT) teaches skills such as attention regulation, distress tolerance, emotion regulation, and effective interpersonal behavior. Some of those targets overlap with problems encountered in ASPD care, particularly impulsive or emotionally escalated conduct. However, much of the stronger DBT literature comes from borderline personality disorder and related clinical populations. That evidence should not be transferred to ASPD as though diagnosis and mechanism made no difference. The 2020 ASPD-focused Cochrane review identified only highly uncertain findings relevant to DBT, and it did not establish DBT as the treatment of choice for ASPD. Gibbon et al., 2020.
Social problem-solving and psychoeducation may help some patients examine alternatives to conflict and strengthen planning. Yet a larger pragmatic randomized study of psychoeducation and problem-solving (PEPS) therapy for adults with a range of personality disorders stopped recruitment early after safety concerns and found no statistically significant improvement in social functioning over usual treatment at 72 weeks. This was not an ASPD-specific efficacy trial. It demonstrates why plausible treatment skills, encouraging early studies, and results from mixed-diagnosis populations need direct replication and safety evaluation. McMurran et al., 2017.
Motivational interviewing, psychodynamic work, supportive psychotherapy, case management, and trauma-informed principles may form part of individualized care. Their use should be described in terms of an actual therapeutic target, the clinician's competence, and the quality of direct evidence in ASPD. Therapeutic popularity or a compelling theory is not sufficient to claim disorder-specific efficacy. In practice, the overall structure, consistency, engagement strategies, and attention to risk can be as consequential as the branded name of an intervention.
Can Medication Treat Antisocial Personality Disorder?
No medication is established as a reliable treatment for the core personality pattern of ASPD. The distinction between prescribing for ASPD and prescribing for a separately diagnosed condition is essential. Someone with ASPD may also have depression, anxiety, ADHD, a substance-use disorder, psychosis, or a medical problem that warrants treatment according to its own evidence and clinical guidelines. That medication can be appropriate without implying it cures ASPD.
A 2020 Cochrane review of pharmacological interventions identified 11 randomized trials with 416 participants with ASPD, approximately 90% of whom were men. The investigators found insufficient evidence to determine the benefits or harms of pharmacological treatments for ASPD. Most trials involved older medications, individual unreplicated studies, and methodological limitations that prevented dependable conclusions. Khalifa et al., Cochrane, 2020.
NICE CG77 advises against routine medication for ASPD itself or its associated aggression, anger, and impulsivity. For co-occurring depression or anxiety, the guideline directs clinicians to the relevant disorder-specific recommendations, with particular attention to adherence, misuse, overdose, and interactions involving alcohol or other substances. NICE prescribing recommendations.
What about antipsychotics, mood stabilizers, or antidepressants?
A clinician may consider a medicine because a clearly identified co-occurring disorder, acute clinical problem, or other specific indication warrants it. That decision requires a documented treatment target, expected benefits, monitoring, side-effect assessment, and review of alternative interventions. Off-label use for aggression or impulsivity is a separate risk–benefit judgment and should not be portrayed as evidence that the medicine treats ASPD's enduring characteristics. Polypharmacy, sedating medication, misuse potential, and drug interactions require special attention in complex cases.
For patients and families, the useful questions are: What precise condition or symptom is this medication treating? How will benefit be measured? What adverse effects are important? When will treatment be reviewed? Could alcohol or another drug change the risk? These questions promote transparent decision-making without inviting someone to start, stop, or adjust psychiatric medication on their own.
Co-Occurring Substance Use: A Major Treatment Priority
Alcohol or drug misuse may intensify conflict, impulsivity, risk-taking, treatment dropout, or exposure to unsafe situations. An ASPD diagnosis should never be a reason to refuse evidence-based addiction care. A coordinated approach may combine therapy for ASPD-related problems with treatment for alcohol, opioid, stimulant, or other substance-use disorders. The evidence for a specific substance-use treatment must be assessed by the substance and treatment outcome rather than being treated as proof of improvement in the underlying personality disorder.
NICE advises offering indicated interventions for substance misuse, including contingency-management programs where suitable, and specialist drug or alcohol treatment within available care pathways. Contingency management uses a structured system of reinforcement for clearly defined behavioral goals. The 2020 psychological-intervention review found limited evidence that certain contingency-management approaches could benefit substance-related outcomes among participants with ASPD; those outcomes should not be equated with broad change in antisocial personality functioning. NICE CG77; Gibbon et al., 2020.
Other conditions also deserve independent assessment. Depression, anxiety, traumatic stress, sleep problems, neurodevelopmental symptoms, and physical-health difficulties can complicate the course of care. Appropriate treatment for these conditions remains worthwhile even if an ASPD-specific program has limited availability. Services should coordinate plans without making the person repeat complex histories unnecessarily or allowing one diagnosis to obscure another.
Why Engagement Matters So Much in ASPD Care
Treatment is difficult to evaluate when participants rarely attend, leave early, or have no reliable follow-up. ASPD studies have often involved considerable treatment attrition, and skepticism about services can be reinforced by previous coercive encounters, stigma, unstable housing, addiction, financial problems, and legal stress. Lack of engagement may reflect these contextual barriers alongside the person's own goals and behavior. A clinician should assess the reasons rather than treat every missed appointment as proof of unwillingness to change.
NICE recommends positive, reinforcing, and respectful engagement; collaboration in treatment choices; clear discussion of consequences; continuity of care; and regular work to sustain motivation. It also recommends considering language, literacy, disabilities, acquired cognitive difficulties, cultural context, and practical barriers when adapting interventions. These recommendations provide a concrete service standard while the intervention evidence continues to develop. NICE: access, autonomy, and engagement.
A workable treatment agreement can identify a few behaviorally defined goals, the responsibilities of the clinician and patient, rules governing confidentiality, what happens after an aggressive episode or missed session, and how progress will be reviewed. People receiving treatment voluntarily and people required to attend by legal order may have different immediate motivations. Collaborative goal setting remains valuable in both circumstances, and a court requirement to attend should never be confused with clinical evidence of benefit.
Safety, Accountability, and Protection of Others
The safety of the person receiving treatment and the safety of other people are legitimate clinical concerns. ASPD does not imply that every patient is violent or that every difficult relationship involves ASPD. When threats, coercion, stalking, interpersonal violence, child-safety concerns, substance intoxication, or severe impulsivity are present, clinicians need a context-sensitive assessment of actual behavior and risk. Risk formulation should incorporate recent incidents, dynamic triggers, access to potential victims, protective factors, co-occurring mental illness, and the practical limits of service capacity.
Treatment can encourage accountability, recognition of consequences, de-escalation, and consistent behavioral change. The presence of a diagnosis should not excuse harm or lead clinicians to assume that affected family members must remain in unsafe contact. Families and partners can seek independent advice and safety support regardless of whether the person engages in treatment. NICE explicitly addresses the needs of carers and children and cautions that services must consider the impact of antisocial behavior and substance misuse on them. NICE guidance for carers and safety.
When there is an immediate threat of serious harm, emergency services and local crisis resources are appropriate. Routine outpatient therapy is not a substitute for urgent safety intervention. In ordinary non-emergency circumstances, a clinician can develop a practical escalation plan: recognizing high-risk situations, limiting access to means of harm when relevant, avoiding alcohol or drugs that worsen control, leaving conflicts early, and contacting appropriate services before a situation becomes dangerous. These are individualized risk-management measures, not a standardized cure.
How Clinicians Assess and Personalize a Treatment Plan
The starting point is a careful diagnostic and functional assessment. Clinicians evaluate persistent behavior over time, developmental history, interpersonal functioning, responsibility, emotion regulation, aggression or victimization where relevant, substance use, medical needs, and the person's own priorities. In the DSM-5 alternative model, identity, self-direction, empathy, and intimacy are dimensions of personality functioning; the ICD-11 model emphasizes severity and trait qualifiers. These frameworks help organize difficulties, but they do not create a simple formula for choosing a psychotherapy. WHO ICD-11 CDDR.
Differential diagnosis is particularly important when apparently antisocial behavior occurs during mania, psychosis, severe intoxication, withdrawal, developmental difficulties, or an acute crisis. Some people present primarily with impulsivity, others with recurrent aggression, detachment, suspiciousness, or chronic conflict. Plans need to reflect the person's actual presentation rather than a stereotyped profile. Screening instruments and risk scales may support professional decisions in particular settings but do not independently diagnose ASPD or predict an individual's future with certainty.
What a realistic treatment plan includes
A high-quality plan names the problems to be addressed, the selected treatment and its evidence status, the frequency and expected duration of contact, relevant co-occurring treatment, any safeguarding requirements, and how improvement will be measured. It should include a process for reviewing the plan when progress is absent or barriers arise. Useful measures may include the frequency and severity of aggressive incidents, attendance, alcohol or drug use, documented behavioral goals, quality of functioning at home and work, and the patient's account of difficulties. No single score captures every important outcome.
A plan also distinguishes learning skills in sessions from consistently applying them outside sessions. Clinicians can rehearse responses to anger, examine patterns that preceded harmful decisions, and revisit concrete incidents without replacing the patient's responsibility for conduct. The therapeutic relationship should permit direct discussion of failures and setbacks, while preserving clear boundaries and ongoing safety assessment.
How Long Does ASPD Treatment Take?
There is no universal duration. The 2025 MOAM trial offered 12 months of specialist MBT-ASPD; the Dutch schema-therapy forensic trial evaluated a three-year intervention. These durations describe the tested programs, not prescriptions for every patient. A person whose primary goals include substance stabilization, improved workplace behavior, or reduction in recurrent violence may need a different combination of services and review periods. Fonagy et al., 2025; Bernstein et al., 2023.
Service interruptions can weaken continuity, particularly when someone moves between correctional, inpatient, outpatient, and community systems. Treatment planning should consider what support remains after a course ends, how gains are monitored, and how setbacks prompt reengagement. Long-term follow-up is important because an outcome observed at the end of a structured program may not remain unchanged when daily conditions change. NICE advises minimizing unnecessary discontinuity and considering ongoing support in relevant high-risk settings. NICE service planning.
Can Someone With ASPD Improve Over Time?
Improvement is possible, although trajectories vary across people and outcomes. A reduction in aggressive incidents or substance-related harm can be clinically valuable even when longstanding interpersonal difficulties continue. Changes in day-to-day responsibility, treatment engagement, and safer decision-making may matter to the individual and those around them. The 2025 MBT-ASPD trial supplies direct evidence of change in aggression within a specific population; it does not answer every long-term recovery question. Fonagy et al., 2025.
A 2023 systematic review and meta-analysis of personality-disorder stability found substantial variation in the persistence of personality-disorder diagnoses and criteria, with important differences between disorders and types of stability. The authors reported comparatively high rank-order stability for antisocial personality-disorder traits, cautioning against simplistic assumptions that every characteristic disappears with age. Persistence of a trait pattern and potential for improved functioning can coexist. d'Huart et al., 2023.
Promises of guaranteed transformation undermine informed consent, while categorical statements that ASPD is untreatable can discourage clinically appropriate care. The defensible goal is measurable, sustained progress in relevant outcomes and access to treatment for co-occurring conditions. Research should ultimately establish which patients benefit most, which components drive outcomes, and what remains after treatment ends.
Finding Appropriate Treatment in the United States
Someone seeking help can begin with a licensed mental health clinician or service experienced in personality-disorder assessment, complex impulsivity, aggression, and co-occurring substance-use conditions. Depending on clinical needs, treatment may involve a psychiatrist, clinical psychologist, specialist psychotherapist, addiction clinician, primary-care professional, and case manager. The appropriate professional mix depends on local availability and the conditions actually present.
Questions worth asking before committing to a program include whether the clinician has experience treating adults with ASPD; what measurable goals the treatment targets; whether the program is an adapted, supervised version of a researched intervention; how co-occurring substance use or depression will be treated; what happens if appointments are missed; how safety and confidentiality are handled; and how progress will be evaluated over time. Asking about a therapist's training or an intervention's evidence is reasonable. A generic claim to “cure antisocial personality” should invite scrutiny.
Access can be complicated by insurance coverage, geographic distance, legal status, and the shortage of specialized services. If a preferred intervention is unavailable, the next step is a coordinated clinical evaluation and an attainable plan using available, appropriate services. Treatment of co-occurring disorders and practical barriers should proceed while specialized options are explored.
Common Misconceptions About ASPD Treatment
ASPD and psychopathy are not identical terms. Psychopathy is a research and assessment construct used in some forensic contexts, while ASPD is a formal categorical DSM diagnosis. Sociopathy is not a distinct DSM-5-TR or ICD-11 diagnosis. Scores on psychopathy instruments cannot be assumed to predict a person's individual response to therapy without appropriate evidence. Likewise, using the phrase “a narcissist” or “a sociopath” in a relationship conflict is not a clinical assessment. A focused explanation appears in Psychopathy, Sociopathy, and Antisocial Personality Disorder.
Aggression and criminal behavior are not interchangeable with ASPD, and the outcomes of a criminal rehabilitation program should not be treated as a full clinical assessment of personality change. The Hub's article on ASPD and criminal behavior separates these issues. For the broader psychotherapy evidence across personality disorders, see Psychotherapy for Personality Disorders: Treatments and Evidence.
The assumption that people with ASPD are incapable of participating in therapy also conflicts with the existence of real treatment trials and with guidance to make services accessible. At the same time, participation in a treatment course is not proof that someone has become safe or has changed every harmful behavior. Observed patterns, respect for boundaries, and continuing risk assessment remain relevant for everyone involved.
Frequently Asked Questions
What is the best treatment for antisocial personality disorder?
No intervention has been established as the best option for every individual. NICE recommends considering structured cognitive and behavioral interventions and treating co-occurring disorders. A 2025 randomized trial found reduced aggression with 12 months of specialist MBT-ASPD among men receiving probation supervision. The most suitable treatment requires clinical assessment of presentation, goals, risks, available trained providers, and evidence limits. NICE CG77; Fonagy et al., 2025.
Is ASPD treatable without medication?
Treatment plans commonly emphasize psychotherapy, behavioral work, clinical support, and care for co-occurring conditions. No drug is established as treating ASPD's core personality pattern. Whether medication is indicated depends on separately assessed conditions and individual risk–benefit considerations. Cochrane pharmacotherapy review.
Does cognitive-behavioral therapy work for ASPD?
Cognitive and behavioral approaches are recommended for consideration by NICE, particularly for impulsivity, interpersonal difficulties, and antisocial behavior. Direct ASPD-specific trials have not demonstrated a uniformly reliable effect across major outcomes. A recommendation for consideration should therefore be distinguished from a guarantee of improvement. Gibbon et al., 2020.
Does dialectical behavior therapy work for ASPD?
DBT skills may be considered for particular emotional and behavioral targets, but disorder-specific evidence is limited. Positive findings in borderline personality disorder cannot independently establish efficacy for ASPD. A clinician should explain the specific target and available supporting evidence rather than present DBT as a proven ASPD cure.
What is mentalization-based treatment for ASPD?
MBT-ASPD is a structured adaptation intended to improve understanding of mental states and reduce maladaptive responses during interpersonal stress. A 2025 randomized trial reported a significant reduction in measured aggression among men on probation. Replication and studies in broader clinical groups remain necessary. Fonagy et al., 2025.
Can treatment reduce violent behavior?
Some interventions aim directly to reduce aggression, and the 2025 MBT-ASPD trial demonstrated improvement on a validated aggression measure in its specified population. A person's risk depends on actual behavior and many dynamic factors. Treatment should include individualized safety assessment and monitoring; no trial result guarantees that a particular individual will not cause harm.
How do I encourage someone with ASPD to get help?
Explain concrete concerns and potential benefits, invite a professional assessment, and offer practical help with access where appropriate. Clear boundaries and independent safety measures remain important. Coercion, threats, or attempts to diagnose the person based on internet lists are poor substitutes for professional care. When someone poses an immediate danger, prioritize emergency safety rather than treatment persuasion. For a wider guide to supportive boundaries, see How to Support Someone With a Personality Disorder.
Can a person with ASPD improve even after multiple failed attempts at therapy?
Yes, meaningful improvement remains possible, although future outcomes cannot be promised. A review may identify a mismatch between treatment and target, untreated addiction or other conditions, an inaccessible program, disruption in services, or engagement barriers. A new assessment can redefine measurable goals, strengthen continuity, and consider suitable specialist options.
Is a person with ASPD automatically a psychopath or a criminal?
No. These terms belong to different clinical, research, and legal frameworks. Formal ASPD diagnosis requires an assessment of a persistent developmental pattern. Individual criminal acts and psychopathy-related constructs do not replace that diagnostic process.
Should loved ones participate in treatment?
Family involvement can help when it is clinically appropriate, freely agreed to, and safe. The patient's consent and confidentiality rights matter, as do the needs and boundaries of family members. Loved ones may benefit from their own support, especially when there is coercion, violence, or significant substance misuse. NICE recommendations on involving carers.
Related Articles
References
Bernstein, D. P., et al. (2023). Schema therapy for violent PD offenders: A randomized clinical trial. Psychological Medicine, 53(1), 88–102. https://doi.org/10.1017/S0033291721001161.
d'Huart, D., et al. (2023). The stability of personality disorders and personality disorder criteria: A systematic review and meta-analysis. Clinical Psychology Review, 102, 102284. https://doi.org/10.1016/j.cpr.2023.102284.
Fonagy, P., et al. (2025). Mentalisation-based treatment for antisocial personality disorder in males convicted of an offence on community probation in England and Wales (MOAM): A multicentre, assessor-blinded, randomised controlled trial. The Lancet Psychiatry, 12(3), 208–219. https://doi.org/10.1016/S2215-0366(24)00445-0.
Gibbon, S., Khalifa, N. R., Cheung, N. H.-Y., Völlm, B. A., & McCarthy, L. (2020). Psychological interventions for antisocial personality disorder. Cochrane Database of Systematic Reviews, CD007668. https://doi.org/10.1002/14651858.CD007668.pub3.
Khalifa, N. R., Gibbon, S., Völlm, B. A., Cheung, N. H.-Y., & McCarthy, L. (2020). Pharmacological interventions for antisocial personality disorder. Cochrane Database of Systematic Reviews, CD007667. https://doi.org/10.1002/14651858.CD007667.pub3.
McMurran, M., et al. (2017). Psychoeducation and problem solving (PEPS) therapy for adults with personality disorder: A pragmatic randomized-controlled trial. Journal of Personality Disorders, 31(6). https://doi.org/10.1521/pedi_2017_31_286.
National Institute for Health and Care Excellence. (2009; reviewed 2024). Antisocial personality disorder: Prevention and management (CG77). https://www.nice.org.uk/guidance/cg77/chapter/Recommendations.
World Health Organization. (2024). Clinical descriptions and diagnostic requirements for ICD-11 mental, behavioural and neurodevelopmental disorders. https://www.who.int/publications/i/item/9789240077263.